GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » EV-to-Revenue

Hainan Poly Pharm Co (SZSE:300630) EV-to-Revenue : 4.34 (As of May. 16, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hainan Poly Pharm Co's enterprise value is ¥7,763 Mil. Hainan Poly Pharm Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was ¥1,788 Mil. Therefore, Hainan Poly Pharm Co's EV-to-Revenue for today is 4.34.

The historical rank and industry rank for Hainan Poly Pharm Co's EV-to-Revenue or its related term are showing as below:

SZSE:300630' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.54   Med: 13.94   Max: 37.31
Current: 4.34

During the past 11 years, the highest EV-to-Revenue of Hainan Poly Pharm Co was 37.31. The lowest was 4.54. And the median was 13.94.

SZSE:300630's EV-to-Revenue is ranked worse than
72.32% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.395 vs SZSE:300630: 4.34

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-16), Hainan Poly Pharm Co's stock price is ¥12.35. Hainan Poly Pharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was ¥3.59. Therefore, Hainan Poly Pharm Co's PS Ratio for today is 3.44.


Hainan Poly Pharm Co EV-to-Revenue Historical Data

The historical data trend for Hainan Poly Pharm Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Poly Pharm Co EV-to-Revenue Chart

Hainan Poly Pharm Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.71 16.49 15.41 16.45 6.79

Hainan Poly Pharm Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.23 6.79 7.67 5.78 6.67

Competitive Comparison of Hainan Poly Pharm Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Poly Pharm Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Poly Pharm Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Poly Pharm Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hainan Poly Pharm Co's EV-to-Revenue falls into.



Hainan Poly Pharm Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hainan Poly Pharm Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=7762.511/1787.887
=4.34

Hainan Poly Pharm Co's current Enterprise Value is ¥7,763 Mil.
Hainan Poly Pharm Co's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,788 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Poly Pharm Co  (SZSE:300630) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hainan Poly Pharm Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=12.35/3.594
=3.44

Hainan Poly Pharm Co's share price for today is ¥12.35.
Hainan Poly Pharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.59.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Poly Pharm Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Poly Pharm Co (SZSE:300630) Business Description

Traded in Other Exchanges
N/A
Address
No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051
Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.

Hainan Poly Pharm Co (SZSE:300630) Headlines

No Headlines